A Combination of Adoptive T Cell Therapy and Ipilimumab Could Increase the Proportion of CR Patients, and Durability of Response
| Drug | Drug Name | Drug Description |
|---|
| Drug | Drug Name | Target | Type |
|---|
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB06186 | Ipilimumab | 2 | Terminated | 1 |